Activation of the JAK/STAT3 pathway confers resistance to breast cancer and breast cancer stem cell lines. Inhibition of JAK/STAT3 led to inhibition of CPT-1b and abolished CSC self-renewal capabilities. Here, STAT3 is linked to breast carcinoma.